112 related articles for article (PubMed ID: 2009320)
21. Kinetic heterogeneity of an experimental tumour revealed by BrdUrd incorporation and mathematical modelling.
Bertuzzi A; Faretta M; Gandolfi A; Sinisgalli C; Starace G; Valoti G; Ubezio P
Bull Math Biol; 2002 Mar; 64(2):355-84. PubMed ID: 11926121
[TBL] [Abstract][Full Text] [Related]
22. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining.
van Dierendonck JH; Wijsman JH; Keijzer R; van de Velde CJ; Cornelisse CJ
Am J Pathol; 1991 May; 138(5):1165-72. PubMed ID: 1673821
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral heterogeneity of S phase transition in solid tumours determined by bromodeoxyuridine labelling and flow cytometry.
Baisch H; Otto U
Cell Prolif; 1993 Sep; 26(5):439-48. PubMed ID: 9087534
[TBL] [Abstract][Full Text] [Related]
24. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder.
Waldman FM; Carroll PR; Cohen MB; Kerschmann R; Chew K; Mayall BH
Mod Pathol; 1993 Jan; 6(1):20-4. PubMed ID: 8093979
[TBL] [Abstract][Full Text] [Related]
25. Proliferative activity of canine mast cell tumours evaluated by bromodeoxyuridine incorporation and Ki-67 expression.
Sakai H; Noda A; Shirai N; Iidaka T; Yanai T; Masegi T; Shirai N; Iidaka T; Yanai T; Masegi T
J Comp Pathol; 2002 Nov; 127(4):233-8. PubMed ID: 12443730
[TBL] [Abstract][Full Text] [Related]
26. Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts.
Bussink J; Kaanders JH; Rijken PF; Martindale CA; van der Kogel AJ
Br J Cancer; 1998; 77(1):57-64. PubMed ID: 9459146
[TBL] [Abstract][Full Text] [Related]
27. Ki-67 and bromodeoxyuridine labeling of human choroidal melanoma cells.
Bardenstein DS; Char DH; Kaleta-Michaels S; Kroll SM
Curr Eye Res; 1991 May; 10(5):479-84. PubMed ID: 1889233
[TBL] [Abstract][Full Text] [Related]
28. Measurement of bromodeoxyuridine labeling index, Ki-67 score and Ag-NOR count in breast carcinomas. Comparison with DNA ploidy.
Sasaki K; Matsumura K; Murakami T; Tsuji T
Oncology; 1992; 49(2):147-53. PubMed ID: 1574251
[TBL] [Abstract][Full Text] [Related]
29. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
[TBL] [Abstract][Full Text] [Related]
30. The significance of Ki-67, BrdU and OKT9 expression in determination of myelodysplastic syndromes by use of APAAP technique.
Yi FH; Wang BM; Liu XF
J Tongji Med Univ; 1993; 13(1):30-3. PubMed ID: 8326526
[TBL] [Abstract][Full Text] [Related]
31. [Clinical and experimental studies on the cellular kinetics in esophageal carcinoma by using monoclonal antibody KI-67].
To Y
Nihon Geka Gakkai Zasshi; 1993 Apr; 94(4):341-51. PubMed ID: 8321181
[TBL] [Abstract][Full Text] [Related]
32. Determination of proliferation index in neoplasms using different Ki-67 equivalent antibodies.
Lindboe CF; von der Ohe G; Torp SH
APMIS; 2003 May; 111(5):567-70. PubMed ID: 12887508
[TBL] [Abstract][Full Text] [Related]
33. Immunocytochemical evaluation of proliferative activity in human brain tumours.
Girino M; Riccardi A; Danova M; Gaetani P; Butti G; Giordano M; Cuomo A
Anal Cell Pathol; 1990 Sep; 2(5):269-75. PubMed ID: 2275874
[TBL] [Abstract][Full Text] [Related]
34. A method to estimate cell cycle time and growth fraction using bromodeoxyuridine-flow cytometry data from a single sample.
Eidukevicius R; Characiejus D; Janavicius R; Kazlauskaite N; Pasukoniene V; Mauricas M; Den Otter W
BMC Cancer; 2005 Sep; 5():122. PubMed ID: 16176590
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric measurement of cell cycle kinetics in rat Walker-256 carcinoma following in vivo and in vitro pulse labelling with bromodeoxyuridine.
Fogt F; Wan J; O'Hara C; Bistrian BR; Blackburn GL; Istfan NW
Cytometry; 1991; 12(1):33-41. PubMed ID: 1825629
[TBL] [Abstract][Full Text] [Related]
36. Cell cycle kinetics in childhood acute leukemia studied with in vitro bromodeoxyuridine labeling, Ki67-reactivity, and flow cytometry.
Tsurusawa M; Aoyama M; Saeki K; Fujimoto T
Leukemia; 1995 Nov; 9(11):1921-5. PubMed ID: 7475284
[TBL] [Abstract][Full Text] [Related]
37. Advanced-stage cervix cancer: rapid tumour growth rather than late diagnosis.
Symonds P; Bolger B; Hole D; Mao JH; Cooke T
Br J Cancer; 2000 Sep; 83(5):566-8. PubMed ID: 10944592
[TBL] [Abstract][Full Text] [Related]
38. Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7).
Guillaud P; du Manoir S; Seigneurin D
Anal Cell Pathol; 1989 Feb; 1(1):25-39. PubMed ID: 2488698
[TBL] [Abstract][Full Text] [Related]
39. Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2'-deoxyuridine labelling: a flow cytometric study of 75 tumours.
Rew DA; Campbell ID; Taylor I; Wilson GD
Br J Surg; 1992 Apr; 79(4):335-9. PubMed ID: 1576503
[TBL] [Abstract][Full Text] [Related]
40. Cell kinetics in vivo of human breast cancer.
Stanton PD; Cooke TG; Forster G; Smith D; Going JJ
Br J Surg; 1996 Jan; 83(1):98-102. PubMed ID: 8653378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
